GE Healthcare and CordenPharma ally on oligonucleotide drug development

Medical Company Product News

GE Healthcare has announced a new partnership with CordenPharma International in the field of oligonucleotide-based drug discovery.

CordenPharma will partner with GE Healthcare's Dharmacon business to create an end-to-end solution that will address the speed and capacity challenges that arise when transitioning from research and preclinical stages to drug development and clinical trials.

“GE Healthcare is forming a strategic collaboration to create an end-to-end solution for oligonucleotide-based drug discovery with CordenPharma International.“

Currently, this changeover requires customers to move from a technology vendor to a contract manufacturing organisation, while also dealing with the capacity challenges that are common in the biotech contract manufacturing marketplace.

Through this partnership, the companies aim to deliver a unified service offering that brings together GE Healthcare's Dharmacon product line - which offers technical expertise in research-scale design and manufacturing - and CordenPharma's expertise in contract manufacturing.

Olivier Loeillot, general manager of GE Healthcare's genomics and cellular research business, said: "We can help customers move faster by working together and provide an offering that takes them from bench to batch with one partner."

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.

See all the latest jobs in Medical Devices
Return to news

Tags